Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BCMA CAR T cells: the winding path to success.

Literature DB >> 31033482

BCMA CAR T cells: the winding path to success.

Abstract

Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen-targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2019 PMID： 31033482 PMCID： PMC6546465 DOI： 10.1172/JCI128372

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

15 in total

1. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy.

Authors: C L Mackall; T A Fleisher; M R Brown; M P Andrich; C C Chen; I M Feuerstein; I T Magrath; L H Wexler; D S Dimitrov; R E Gress
Journal: Blood Date: 1997-05-15 Impact factor: 22.113

2. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Authors: Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone
Journal: J Clin Invest Date: 2019-03-21 Impact factor: 14.808

3. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

4. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors: Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal: Blood Date: 2016-07-13 Impact factor: 22.113

5. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal: Sci Transl Med Date: 2016-09-07 Impact factor: 17.956

6. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.

Authors: Roberto Bellucci; Edwin P Alyea; Sabina Chiaretti; Catherine J Wu; Emmanuel Zorn; Edie Weller; Bingyan Wu; Christine Canning; Robert Schlossman; Nikhil C Munshi; Kenneth C Anderson; Jerome Ritz
Journal: Blood Date: 2005-02-03 Impact factor: 22.113

7. Characterization of clonogenic multiple myeloma cells.

Authors: William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal: Blood Date: 2003-11-20 Impact factor: 22.113

8. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

Authors: John Rossi; Patrick Paczkowski; Yueh-Wei Shen; Kevin Morse; Brianna Flynn; Alaina Kaiser; Colin Ng; Kyle Gallatin; Tom Cain; Rong Fan; Sean Mackay; James R Heath; Steven A Rosenberg; James N Kochenderfer; Jing Zhou; Adrian Bot
Journal: Blood Date: 2018-06-12 Impact factor: 22.113

9. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Authors: Stephanie L Goff; Mark E Dudley; Deborah E Citrin; Robert P Somerville; John R Wunderlich; David N Danforth; Daniel A Zlott; James C Yang; Richard M Sherry; Udai S Kammula; Christopher A Klebanoff; Marybeth S Hughes; Nicholas P Restifo; Michelle M Langhan; Thomas E Shelton; Lily Lu; Mei Li M Kwong; Sadia Ilyas; Nicholas D Klemen; Eden C Payabyab; Kathleen E Morton; Mary Ann Toomey; Seth M Steinberg; Donald E White; Steven A Rosenberg
Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544

10. BCMA is essential for the survival of long-lived bone marrow plasma cells.

Authors: Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle
Journal: J Exp Med Date: 2004-01-05 Impact factor: 14.307

4 in total

1. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors: Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal: Blood Adv Date: 2020-09-08